EUCTR2016-001202-42-DE进行中（未招募）1 期
A Phase II, Open-Label, Multi-Arm Study to Determine the PreliminaryEfficacy of Novel Combinations of Treatment in Patients with PlatinumRefractory Extensive-Stage Small-Cell Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria (applicable to all arms)
- •- Adults with ED SCLC who have have demonstrated progressive disease either during first-line platinum-based chemotherapy (platinum
- •refractory) or within 90 days of completing platinum basedchemotherapy (platinum resistant) and have not received further treatment.
- •- Brain metastases must be asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.
- •- At least 1 lesion, not previously irradiated, that can be accurately measured at baseline.
- •- Life expectancy of at least 8 weeks.
- •- Adequate organ and marrow function
- •- WHO/ECOG PS of 0-1 at enrollment
- •Inclusion criteria (Arm A specific)
- •- Body weight >30 kg.
- •- No prior exposure to immune mediated therapy, excluding therapeutic anticancer vaccines.
- •Inclusion criteria (Arm B specific)
- •- Able and willing to swallow oral medication
- •Inclusion Criteria (Arm C specific)
- •-Able and willing to swallow oral medication
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •Exclusion criteria (applicable to all arms)
- •- Participation in another clinical study, major surgery, radiation therapy within 28 days.
- •- Any condition that, in the opinion of the Investigator, would interfere with the evaluation of the IP or interpretation of patient safety or study
- •- History of ILD, another primary malignancy, leptomeningeal carcinomatosis or spinal cord compression
- •Exclusion criteria (Arm A specific)
- •- Any concurrent cancer treatment.
- •- Live vaccines within 30 days.
- •- Known hypersensitivity to IP or excipient.
- •- Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study.
- •- Active autoimmune disease, including a paraneoplastic syndrome of autoimmune nature.
- •- Active or prior documented autoimmune or inflammatory disorders.
- •- Any unresolved toxicity (CTCAE Grade >2) from previous anticancer therapy.
- •- History of allogenic organ transplantation or active primary immunodeficiency.
- •- Active infection.
- •- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab.
- •Exclusion criteria (Arm B specific)
- •- Prior exposure to any WEE1 inhibitors.
- •- Products known to be sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong
- •inhibitors/inducers of CYP3A4. Coadministration of rosuvastatin, aprepitant or fosaprepitant or any herbal preparations.. Grapefruit and
- •Seville oranges should be avoided while taking AZD1775.
- •- Any known hypersensitivity or contraindication to IP or CBDP.
- •- QTcF > 470 msec or congenital long QT syndrome.
- •- Any current or within 6 months cardiac diseases NYHA = Class 2:
- •unstable angina pectoris, congestive heart failure, acute MI, conduction abnormality not controlled with pacemaker or medication, significant ventricular or supraventricular arrhythmias.
- •- A recent history of Torsades de pointes
- •Exclusion criteria (Arm C specific)
- •- Cytotoxic chemotherapy within 21 days of Cycle 1 Day 1 is not permitted
- •- Previous treatment with a PARP inhibitor (including olaparib) or ATR inhibitor
- •- Concomitant use of known strong CYP3A inhibitors or moderate CYP3A inhibitors
- •- Concomitant use of known strong or moderate CYP3A inducers
- •- Persisting (> 4 weeks) severe pancytopenia due to previous therapy
- •- Cardiac dysfunction
- •- Refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection
- •- Patients with uncontrolled seizures
- •- Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks before the dosing.
研究者
相似试验
进行中（未招募）
1 期
A phase II, open label, multiarm study to assess the efficay of new drugs in patients with Small Cell Lung Cancer whose cancer worsened during or within 90 days of platinum based chemotherapyPatients with extensive-stage small-cell lung cancer (ED-SCLC) who have refractory or resistantdisease from prior platinum-based chemotherapy.MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001202-42-PLAstraZeneca AB60
进行中（未招募）
1 期
A phase II, open label, multiarm study to assess the efficay of new drugs in patients with Small Cell Lung Cancer whose cancer worsened during or after 90 days of platinum based chemotherapyPatients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistantdisease from prior platinum-based chemotherapy.MedDRA version: 19.0Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001202-42-ESAstraZeneca AB40
进行中（未招募）
1 期
A phase II, open label, multiarm study to assess the efficay of new drugs in patients with Small Cell Lung Cancer whose cancer worsened during or within 90 days of platinum based chemotherapyEUCTR2016-001202-42-HUAstraZeneca AB60
招募中
1 期
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaMedDRA version: 21.0Level: PTClassification code: 10060121Term: Squamous cell carcinoma of head and neck Class: 100000004864CTIS2023-503418-63-00Beigene Ltd.160
尚未招募
2 期
An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients with Paroxysmal Nocturnal HemoglobinuriaPNH10018911NL-OMON54475Apellis1